Department of Pediatrics, Graduate School of Medicine, Kyoto University, 54 Kawahara-Cho, Shogoin, Sakyo-Ku, Kyoto City, Kyoto, 606-8507, Japan.
Department of Pediatric Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-Cho, Shogoin, Sakyo-Ku, Kyoto City, Kyoto, 606-8507, Japan.
Pediatr Cardiol. 2024 Jun;45(5):1142-1150. doi: 10.1007/s00246-023-03121-0. Epub 2023 Feb 8.
Portopulmonary hypertension is an intractable form of pulmonary hypertension. Although liver transplantation is recommended for patients who respond poorly to treatments, the mechanisms by which liver transplantation improves pulmonary hypertension remain unclear. The present study investigated these mechanisms by retrospectively evaluating patients' data. This study retrospectively evaluated echocardiography and catheterization data before and after liver transplantation in 12 patients who underwent liver transplantation from 2001 to 2019. The 12 patients included one male and 11 females, of median age at liver transplantation of 10 years, 2 months. Nine patients underwent liver transplantation for congenital biliary atresia and three for portal vein aplasia or hypoplasia. Mean pulmonary arterial pressure was 44.1 ± 8.1 mmHg at the first cardiac catheter examination, 35.3 ± 7.8 mmHg before liver transplantation, and 29.5 ± 9.3 mmHg 6 months after liver transplantation. Pulmonary artery pressure was reduced by treatments of pulmonary hypertension and by liver transplantation. Pulmonary vascular resistance did not differ before and after liver transplantation, whereas the cardiac index decreased significantly, indicating that the significant reduction in mean pulmonary artery pressure was due to a decrease in cardiac index. Decreased cardiac index was thought to result from improvements in hyperdynamic conditions due to increased (normalized) systemic vascular resistance. Liver transplantation likely suppresses shear stress on pulmonary arteries, preventing further damage by hyper-circulation. A longer-term evaluation is required to determine the effect of improving pulmonary artery remodeling.
肝移植治疗难治性肺动脉高压的机制研究
肝移植治疗难治性肺动脉高压的机制研究
肝移植治疗难治性肺动脉高压的机制研究
肝移植治疗难治性肺动脉高压是一种棘手的肺动脉高压形式。虽然对于治疗反应不佳的患者推荐进行肝移植,但肝移植改善肺动脉高压的机制仍不清楚。本研究通过回顾性评估患者数据来探讨这些机制。本研究回顾性评估了 2001 年至 2019 年间 12 例接受肝移植患者的超声心动图和心导管检查数据。这 12 例患者包括 1 例男性和 11 例女性,肝移植时的中位年龄为 10 岁 2 个月。9 例患者因先天性胆道闭锁行肝移植,3 例因门静脉缺如或发育不良行肝移植。首次心导管检查时平均肺动脉压为 44.1±8.1mmHg,肝移植前为 35.3±7.8mmHg,肝移植后 6 个月时为 29.5±9.3mmHg。肺动脉压通过肺动脉高压治疗和肝移植得到降低。肝移植前后肺血管阻力无差异,而心指数显著下降,表明平均肺动脉压的显著降低是由于心指数的降低。心指数的降低可能是由于全身性血管阻力增加(标准化)导致高动力状态得到改善。肝移植可能抑制了肺动脉的切应力,防止了高循环引起的进一步损伤。需要进行更长期的评估,以确定改善肺动脉重塑的效果。